Related references
Note: Only part of the references are listed.Overview of Myeloproliferative Neoplasms History, Pathogenesis, Diagnostic Criteria, and Complications
Douglas Tremblay et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2021)
Impact of NFE2 mutations on AML transformation and overall survival in patients with myeloproliferative neoplasms
Clemence Marcault et al.
BLOOD (2021)
Impact of Mutational Profile on the Management of Myeloproliferative Neoplasms: A Short Review of the Emerging Data
Giuseppe G. Loscocco et al.
ONCOTARGETS AND THERAPY (2020)
Altered NFE2 activity predisposes to leukemic transformation and myelosarcoma with AML-specific aberrations
Jonas Samuel Jutzi et al.
BLOOD (2019)
Classification and Personalized Prognosis in Myeloproliferative Neoplasms
J. Grinfeld et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
MPN patients harbor recurrent truncating mutations in transcription factor NF-E2
Jonas S. Jutzi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Leukemic blasts in transfon-ned JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation
Alexandre Theocharides et al.
BLOOD (2007)
Mutation of JAK2 in the myeloproliferative disorders:: timing, clonality studies, cytogenetic associations, and role in leukemic transformation
Peter J. Campbell et al.
BLOOD (2006)
Share Paper
